Emerging new threat of the older G5 Japanese encephalitis virus

NewsGuard 100/100 Score

Announcing a new article publication for Zoonoses journal. Japanese encephalitis (JE) is an important viral encephalitis with epidemic status in Asia, which is caused by Japanese encephalitis virus (JEV), a member of the genus Flavivirus.

JEV is divided into five genotypes. Genotype 5 (G5) is relatively neglected because of the limited number of cases and strains isolated. The first strain of G5 JEV (Muar strain) was isolated in Singapore in 1952 in a patient from Muar, Malaysia. The second strain (XZ0934) was isolated 57 years later in China, thus indicating the re-emergence of G5 JEV. A female patient who had been vaccinated against JE was infected with G5 JEV in Korea in 2015. JE is a vaccine-preventable disease, and its incidence has decreased with vaccination in many Asian countries.

G3 JEV is the main candidate for current JE vaccines, which include attenuated, inactivated and chimeric type vaccines. However, the available vaccines do not provide adequate protection against the older G5 JEV lineage.

More research on this genotype is crucial for developing better detection methods, expanding surveillance to determine the possible chains of viral transmission for this new threat and developing a polyvalent JEV vaccine.

Journal reference:

Zhang, W., et al. (2022) Genotype 5 Japanese Encephalitis Virus—Old Genotype, New Threat. Zoonoses. doi.org/10.15212/ZOONOSES-2022-0016.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vaccine strategy targets SARS-CoV-2's stable S2 subunit, offering broad protection against evolving variants